Drugs / Actinium (225Ac) rhPSMA-10.1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07414940 | Apr 2026 → Mar 2031 expected | castration-resistant prostate carcinoma, metastatic prostate carcinoma | University College, London | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-07-09 | Blue Earth Therapeutics Ltd | Blue Earth Therapeutics announces first participant dosed in Phase 1 clinical trial investigating Actinium (225Ac) rhPSMA-10.1 Injection in metastatic castration-resistant prostate cancer blueearththerapeutics.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Actinium (225Ac) rhPSMA-10.1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07414940 ↗ |
| Action | Deplete | “attach to prostate cancer cells in the body and destroy them using ionising radiation” NCT07414940 ↗ |